Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special use results survey of Enhertu for ILD in unresectable advanced or recurrent lung cancer
jRCT2031230346Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Primary: ILD expression based on the judgement result of ILD outside judgment Committee. Started Nov 2023; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031230346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230346.